Amundi Has $15.90 Million Holdings in Penumbra, Inc. $PEN

Amundi decreased its position in shares of Penumbra, Inc. (NYSE:PEN) by 48.8% in the 2nd quarter, HoldingsChannel reports. The fund owned 63,673 shares of the company’s stock after selling 60,636 shares during the period. Amundi’s holdings in Penumbra were worth $15,902,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Machina Capital S.A.S. acquired a new position in Penumbra during the second quarter worth $369,000. Fortis Capital Advisors LLC acquired a new position in shares of Penumbra during the first quarter valued at about $732,000. Belpointe Asset Management LLC bought a new stake in shares of Penumbra during the first quarter worth about $732,000. Janney Montgomery Scott LLC increased its position in shares of Penumbra by 716.5% during the second quarter. Janney Montgomery Scott LLC now owns 24,749 shares of the company’s stock worth $6,351,000 after acquiring an additional 21,718 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in shares of Penumbra by 22.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 26,604 shares of the company’s stock worth $6,827,000 after acquiring an additional 4,960 shares during the last quarter. 88.88% of the stock is owned by institutional investors and hedge funds.

Penumbra Stock Performance

PEN stock opened at $302.89 on Thursday. The company has a quick ratio of 4.18, a current ratio of 6.73 and a debt-to-equity ratio of 0.02. The firm has a market cap of $11.86 billion, a PE ratio of 72.46, a P/E/G ratio of 2.37 and a beta of 0.66. The business has a 50 day moving average of $266.75 and a 200-day moving average of $258.56. Penumbra, Inc. has a 12-month low of $221.26 and a 12-month high of $310.00.

Penumbra (NYSE:PEN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.07. The business had revenue of $354.69 million for the quarter, compared to analyst estimates of $340.77 million. Penumbra had a return on equity of 11.35% and a net margin of 12.30%.Penumbra’s quarterly revenue was up 17.8% compared to the same quarter last year. During the same period last year, the company posted $0.85 earnings per share. As a group, sell-side analysts expect that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Insider Activity

In other news, EVP Johanna Roberts sold 300 shares of Penumbra stock in a transaction on Friday, December 5th. The stock was sold at an average price of $300.13, for a total transaction of $90,039.00. Following the sale, the executive vice president directly owned 63,836 shares in the company, valued at $19,159,098.68. The trade was a 0.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Arani Bose sold 7,500 shares of the stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $300.19, for a total transaction of $2,251,425.00. Following the transaction, the director owned 275,261 shares of the company’s stock, valued at approximately $82,630,599.59. The trade was a 2.65% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 19,744 shares of company stock valued at $5,755,174 in the last ninety days. 4.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Wall Street Zen downgraded Penumbra from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Needham & Company LLC restated a “buy” rating and issued a $326.00 target price on shares of Penumbra in a report on Monday, October 27th. Canaccord Genuity Group lifted their target price on Penumbra from $350.00 to $355.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Evercore ISI reissued an “outperform” rating and issued a $286.00 price target on shares of Penumbra in a research report on Thursday, November 6th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Penumbra in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $305.69.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.